Correct (2): Montelukast has an FDA boxed warning for serious neuropsychiatric events — agitation, depression, sleep disturbances, hallucinations, irritability, hostility, anxiety, and suicidal thoughts/behavior, especially in children/adolescents. Parents and patients must be counseled to report symptoms immediately. (1) Routine LFT not required for montelukast (different from zafirlukast). (3,4) Unrelated.
For study reference only. Always follow current clinical guidelines and your institution’s protocols.